Castle Biosciences INC Form 4 insider transactions

Castle Biosciences CEO Derek Maetzold sold shares of common stock on March 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences, reports the acquisition of 55,243 Restricted Stock Units (RSUs) on March 4, 2024, according to a Form 4 filing with the SEC.

Kristen M Oelschlager, COO of Castle Biosciences, reports the acquisition of 55,243 Restricted Stock Units (RSUs) on March 4, 2024, vesting annually starting March 4, 2025.

Frank Stokes, CFO of Castle Biosciences, acquired 48,744 Restricted Stock Units (RSUs) on March 4, 2024, according to a recent SEC filing.

Castle Biosciences CEO Derek Maetzold reports the acquisition and disposal of company stock, including the vesting of restricted stock units and the exercise of stock options.

Director Daniel Bradbury executed sales of Castle Biosciences (CSTL) common stock on March 4, 2024, under a pre-arranged 10b5-1 trading plan.